Brief: Ascletis Pharma Says IND Application Of Asc10 Oral Inhibitor Drug Targeting Rna-Dependent Rna Polymerase For Covid-19, Accepted By NMPA
04/08/2022 02:24
Aug 4 (Reuters) - Ascletis Pharma Inc 1672.HK :
* IND APPLICATION OF ASC10 ORAL INHIBITOR DRUG TARGETING
RNA-DEPENDENT RNA POLYMERASE FOR COVID-19, ACCEPTED BY NMPA
Source text for Eikon: ID:
Further company coverage: 1672.HK
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026